PEMPHIGUS

This study tests a new drug called B007 in 132 people with pemphigus, a serious blistering skin disease. The goal is to see if B007 can help patients achieve complete remission while using minimal other treatments. Participants receive injections of B007 at high or low doses, and…

This study tests a new drug called CM336 in 30 adults with moderate to severe autoimmune bullous disease, a condition where the immune system attacks the skin causing painful blisters. The drug targets specific immune cells to reduce this attack. The main goal is to see if the dr…

This study tests a personalized approach to treating pemphigus, a rare blistering skin disease. Instead of waiting for a relapse, doctors will use blood tests to measure specific antibodies and give extra rituximab infusions only when those levels rise. The goal is to prevent fla…

This phase 3 study tests an experimental drug called tirabrutinib for people with pemphigus, a rare autoimmune disease that causes painful blisters on skin and mucous membranes. The trial enrolls 34 adults whose disease is not well controlled by steroids. Participants receive eit…

This study aims to create a large collection of blood samples and medical information from 800 people with autoimmune or inflammatory skin diseases. Researchers will use these samples to find new biomarkers and better understand what causes these conditions. The goal is to help d…

This study aims to understand the full burden of 9 rare skin diseases—including physical, emotional, social, and financial challenges—on patients and their families. Researchers will use special questionnaires to track how these conditions affect daily life and care needs. About …